Guideline

Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024.

Year of Publication

2024

Issuing Institution

World Health Organization

Links

Recommendations

2 included recommendations

WHO suggests using the 9-month all-oral regimens (BLMZ, BLLfxCZ and BDLLfxZ) over currently recommended longer (>18 months) regimens in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded. Amongst these regimens, using BLMZ is suggested over using BLLfxCZ, and BLLfxCZ is suggested over BDLLfxZ

Status

Maintained

Recommended in favor

Conditional

Certainty of evidence

Very low

WHO suggests the use of a 6-month treatment regimen composed of bedaquiline, delamanid, linezolid (600 mg), levofloxacin, and clofazimine (BDLLfxC) in MDR/RR-TB patients with or without fluoroquinolone resistance

Status

New

Recommended in favor

Conditional

Certainty of evidence

Very low